Form 4: Neurocrine Biosciences Officer Exercises Options and Sells Shares Under 10b5-1 Plan

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares according to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 6, 2024, Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised options to acquire 273 shares of common stock at a price of $79.02 per share.
• Simultaneously, Delaet sold 273 shares of common stock at $140.55 per share.
• These transactions were executed under a pre-existing Rule 10b5-1 trading plan adopted on November 29, 2023.
• Following these transactions, Delaet directly owns 7,507 shares of Neurocrine Biosciences common stock and holds options for 4,899 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not necessarily reflect a change in the officer's outlook on the company.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating no insider information was used.

Industry Context

Insider transactions are routinely monitored and reported to the SEC. Rule 10b5-1 plans are a common mechanism for corporate insiders to sell shares without raising concerns about insider trading.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a standard practice among executives at publicly traded companies, including those in the biotechnology sector like Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB).
• These plans allow insiders to sell shares over time in a predetermined manner, mitigating concerns about trading on non-public information.
• The reported transactions are typical in terms of volume and execution strategy compared to similar filings from executives at comparable companies.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on stakeholders as they are part of a pre-arranged trading plan.

Key Dates